Characterization of currently marketed heparin products: Adverse event relevant bioassays

Journal of Pharmaceutical and Biomedical Analysis

Volumn 67-68, Issue , 2012, Pages 28-35

  Sommers, Cynthia D ^a   Montpas, Nicolas ^b   Adam, Albert ^b   Keire, David A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Bradykinin; Compliment activation; Heparin; Kallikrein activity; OSCS; Protamine

Indexed keywords

BRADYKININ; CHONDROITIN SULFATE; COMPLEMENT COMPONENT C5A; DALTEPARIN; DERMATAN SULFATE; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; KALLIKREIN; OVERSULFATED CHONDROITIN SULFATE; OVERSULFATED DERMATAN SULFATE; OVERSULFATED HEPARAN SULFATE; PROTAMINE; TINZAPARIN; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MARKETING; DRUG SULFATION; PRIORITY JOURNAL;

BIOLOGICAL ASSAY; HEPARIN; HUMANS;

EID: 84862120795     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.04.017     Document Type: Article

References (30)

1. McMahon A.W., Pratt R.G., Hammad T.A., Kozlowski S., Zhou E., Lu S., Kulick C.G., Mallick T., Dal Pan G. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. Pharmacoepidemiol. Drug Safety 2008, 19:921-933.
2. Blossom D.B., Kallen A.J., Patel P.R., Elward A., Robinson L., Gao G., Langer R., Perkins K.M., Jaeger J.L., Kurkjian K.M., Jones M., Schillie S.F., Shehab N., Ketterer D., Venkataraman G., Kishimoto T.K., Shriver Z., McMahon A.W., Austen K.F., Kozlowski S., Srinivasan A., Turabelidze G., Gould C.V., Arduino M.J., Sasisekharan R. Outbreak of adverse reactions associated with contaminated heparin. N. Engl. J. Med. 2008, 359:2674-2684.
3. Silverberg M., Diehl S.V. The activation of the contact system of human plasma by polysaccharide sulfates. Ann. N. Y. Acad. Sci. 1987, 516:268-279.
4. Corbier A., Le Berre N., Rampe D., Meng H., Lorenz M., Vicat P., Potdevin S., Doubovetzky M. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat. Toxicol. Sci. 2011, 121:417-427.
5. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.J., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358:2457-2467.
6. Adam A., Montpas N., Keire D., Desormeaux A., Brown N.J., Marceau F., Westenberger B. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 31:5741-5748.
7. McKee J., Bairstow S., Szabo C., Ray J., Wielgos T., Hu P., Chess E., Nordhaus M., Hai T., Campbell J., Donovan S., Viseux N., Riedel N., Cammack J., Johnson R. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin. J. Clin. Pharmacol. 2010, 50:1159-1170.
8. Qian Y., Pan J., Zhou X., Weiser P., Lu H., Zhang L. Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis. Prog. Mol. Biol. Transl. Sci. 2010, 93:395-421.
9. Schwartz L.B. Heparin comes clean. N. Engl. J. Med. 2008, 358:2505-2509.
10. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 2005, 99:6-38.
11. Li B., Suwan J., Martin J.G., Zhang F., Zhang Z., Hoppensteadt D., Clark M., Fareed J., Linhardt R.J. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem. Pharmacol. 2009, 78:292-300.
12. Keire D.A., Trehy M.L., Reepmeyer J.C., Kolinski R.E., Ye W., Dunn J., Westenberger B.J., Buhse L.F. Analysis of crude heparin by (1)H NMR capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate. J. Pharm. Biomed. Anal. 2010, 51:921-926.
13. Sommers C.D., Mans D.J., Mecker L.C., Keire D.A. Sensitive detection of oversulfated chondroitin sulfate in heparin sodium or crude heparin with a colorimetric microplate based assay. Anal. Chem. 2011, 83:3422-3430.
14. Sommers C.D., Keire D.A. Detection of possible economically motivated adulterants in heparin sodium and low molecular weight heparins with a colorimetric microplate based assay. Anal. Chem. 2011, 83:7102-7108.
15. Keire D.A., Mans D.J., Ye H., Kolinski R.E., Buhse L.F. Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR SAX-HPLC, and anticoagulation time approaches. J. Pharm. Biomed. Anal. 2010, 52:656-664.
16. Bairstow S., McKee J., Nordhaus M., Johnson R. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products. Anal. Biochem. 2009, 388:317-321.
17. Tami C., Puig M., Reepmeyer J.C., Ye H., D'Avignon D.A., Buhse L., Verthelyi D. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials 2008, 29:4808-4814.
18. Toida T., Sakai S., Akiyama H., Linhardt R.J. Immunological activity of chondroitin sulfate. Adv. Pharmacol. 2006, 53:403-415.
19. Ramacciotti E., Clark M., Sadeghi N., Hoppensteadt D., Thethi I., Gomes M., Fareed J. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications. Clin. Appl. Thromb. Hemost. 2011, 17:126-135.
20. Chudasama S.L., Espinasse B., Hwang F., Qi R., Joglekar M., Afonina G., Wiesner M.R., Welsby I.J., Ortel T.L., Arepally G.M. Heparin modifies the immunogenicity of positively charged proteins. Blood 2010, 116:6046-6053.
21. Schroeder M., Hogwood J., Gray E., Mulloy B., Hackett A.M., Johansen K.B. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Anal. Bioanal. Chem. 2010, 399:763-771.
22. Maurer J., Haselbach S., Klein O., Baykut D., Vogel V., Mantele W. Analysis of the complex formation of heparin with protamine by light scattering and analytical ultracentrifugation: implications for blood coagulation management. J. Am. Chem. Soc. 2010, 133:1134-1140.
23. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 1998, 306:35-43.
24. Decarie A., Drapeau G., Closset J., Couture R., Adam A. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 1994, 15:511-518.
25. Keire D.A., Ye H., Trehy M.L., Ye W., Kolinski R.E., Westenberger B.J., Buhse L.F., Nasr M., Al-Hakim A. Characterization of currently marketed heparin products: key tests for quality assurance. Anal. Bioanal. Chem. 2010, 399:581-591.
26. Law R.H., Zhang Q., McGowan S., Buckle A.M., Silverman G.A., Wong W., Rosado C.J., Langendorf C.G., Pike R.N., Bird P.I., Whisstock J.C. An overview of the serpin superfamily. Genome Biol. 2006, 7:216.
27. Crowther M.A., Berry L.R., Monagle P.T., Chan A.K. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br. J. Haematol. 2002, 116:178-186.
28. Ramamurthy N., Baliga N., Wakefield T.W., Andrews P.C., Yang V.C., Meyerhoff M.E. Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes. Anal. Biochem. 1999, 266:116-124.
29. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
30. Hamad O.A., Ekdahl K.N., Nilsson P.H., Andersson J., Magotti P., Lambris J.D., Nilsson B. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J. Thromb. Haemost. 2008, 6:1413-1421.